Phase II study of etoposide and alpha-interferon in patients with advanced measurable colorectal carcinoma.

Journal Article

Based on encouraging in vitro and in vivo data, 14 consecutive patients with measurable metastatic previously untreated colorectal carcinoma were treated with a combination of intravenous etoposide and subcutaneous alpha-interferon. Etoposide was given at 60 mg/m2 intravenously on days 1-5 and alpha-interferon at 5 million units/m2 subcutaneously on days 1-5; courses were repeated every 21 days. All 14 patients were evaluable for response and toxicity. None of the patients achieved a complete or partial remission. Toxicity of this combination was moderate. Our data suggest that this combination is ineffective against colorectal carcinoma.

Full Text

Duke Authors

Cited Authors

  • Ajani, JA; Abbruzzese, JL; Markowitz, AB; Patt, YZ; Daugherty, K

Published Date

  • February 1993

Published In

Volume / Issue

  • 11 / 1

Start / End Page

  • 67 - 69

PubMed ID

  • 8349439

Electronic International Standard Serial Number (EISSN)

  • 1573-0646

International Standard Serial Number (ISSN)

  • 0167-6997

Digital Object Identifier (DOI)

  • 10.1007/bf00873914

Language

  • eng